Australia's most trusted
source of pharma news
Wednesday, 16 October 2024
Posted 14 October 2024 AM
Bayer has registered a pre-filled syringe of its high-dose Eylea, which provides an easy and accurate way to administer the blockbuster eye drug.
Eylea 114.3 mg/mL, also known as Eylea 8 mg was first approved for intravitreal injection vial with needle in June and recently listed on the PBS for patients with wet age-related macular degeneration and diabetic macular oedema, joining the existing 2 mg strength.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.